Eli Lilly reported a 39% increase in revenue driven by a 53% rise in volume, despite a 15% decline in realized prices. The company's gross margin improved to 83.9%, reflecting strong operational efficiency. Most revenue comes from the obesity drug tirzepatide, which poses concentration risk as patent expiration and pricing pressures approach. Eli Lilly is reinvesting profits into new drug development to offset future losses from exclusivity expiration.
Eli Lilly shares trade at USD 1,423.82 on Pluang as of Nov 04, 2026 18:01 WIB, up 1.02% for the day. The stock shows balanced investor interest with 59% buy orders and a typical hold time of 94 days. Its market cap stands at $1.26 trillion, reflecting its large health sector presence.
Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscie...
The AI-driven bull market faces challenges as investors rotate from high-spending tech stocks like Nvidia to traditionally defensive stocks such as Walmart and Eli Lilly. Despite strong earnings in some tech sectors, the Nasdaq-100 and semiconductor ...
Eli Lilly reported strong recent financial results with solid revenue growth and robust margins, even raising its guidance. However, signs of slowing revenue growth in the near future could impact margins and temper enthusiasm. Despite this, Eli Lill...
Eli Lilly, having reached a $1.146 trillion market cap largely due to weight-loss drugs Mounjaro and Zepbound, is now showing strong growth potential in oncology, immunology, and neuroscience sectors, with Q2 revenue from these areas up 121% year ove...
